Home > Research > Publications & Outputs > Treatment-control comparisons in platform trial...

Electronic data

  • 2407.13546v1

    Accepted author manuscript, 905 KB, PDF document

Keywords

View graph of relations

Treatment-control comparisons in platform trials including non-concurrent controls

Research output: Working paperPreprint

Published

Standard

Treatment-control comparisons in platform trials including non-concurrent controls. / Roig, Marta Bofill; Krotka, Pavla; Hees, Katharina et al.
2024.

Research output: Working paperPreprint

Harvard

Roig, MB, Krotka, P, Hees, K, Koenig, F, Magirr, D, Jacko, P, Parke, T & Posch, M 2024 'Treatment-control comparisons in platform trials including non-concurrent controls'.

APA

Roig, M. B., Krotka, P., Hees, K., Koenig, F., Magirr, D., Jacko, P., Parke, T., & Posch, M. (2024). Treatment-control comparisons in platform trials including non-concurrent controls.

Vancouver

Roig MB, Krotka P, Hees K, Koenig F, Magirr D, Jacko P et al. Treatment-control comparisons in platform trials including non-concurrent controls. 2024 Jul 18.

Author

Roig, Marta Bofill ; Krotka, Pavla ; Hees, Katharina et al. / Treatment-control comparisons in platform trials including non-concurrent controls. 2024.

Bibtex

@techreport{dc0e9139b99742fca48b67fb2899f290,
title = "Treatment-control comparisons in platform trials including non-concurrent controls",
abstract = "Shared controls in platform trials comprise concurrent and non-concurrent controls. For a given experimental arm, non-concurrent controls refer to data from patients allocated to the control arm before the arm enters the trial. The use of non-concurrent controls in the analysis is attractive because it may increase the trial's power of testing treatment differences while decreasing the sample size. However, since arms are added sequentially in the trial, randomization occurs at different times, which can introduce bias in the estimates due to time trends. In this article, we present methods to incorporate non-concurrent control data in treatment-control comparisons, allowing for time trends. We focus mainly on frequentist approaches that model the time trend and Bayesian strategies that limit the borrowing level depending on the heterogeneity between concurrent and non-concurrent controls. We examine the impact of time trends, overlap between experimental treatment arms and entry times of arms in the trial on the operating characteristics of treatment effect estimators for each method under different patterns for the time trends. We argue under which conditions the methods lead to type 1 error control and discuss the gain in power compared to trials only using concurrent controls by means of a simulation study in which methods are compared.",
keywords = "stat.ME",
author = "Roig, {Marta Bofill} and Pavla Krotka and Katharina Hees and Franz Koenig and Dominic Magirr and Peter Jacko and Tom Parke and Martin Posch",
year = "2024",
month = jul,
day = "18",
language = "English",
type = "WorkingPaper",

}

RIS

TY - UNPB

T1 - Treatment-control comparisons in platform trials including non-concurrent controls

AU - Roig, Marta Bofill

AU - Krotka, Pavla

AU - Hees, Katharina

AU - Koenig, Franz

AU - Magirr, Dominic

AU - Jacko, Peter

AU - Parke, Tom

AU - Posch, Martin

PY - 2024/7/18

Y1 - 2024/7/18

N2 - Shared controls in platform trials comprise concurrent and non-concurrent controls. For a given experimental arm, non-concurrent controls refer to data from patients allocated to the control arm before the arm enters the trial. The use of non-concurrent controls in the analysis is attractive because it may increase the trial's power of testing treatment differences while decreasing the sample size. However, since arms are added sequentially in the trial, randomization occurs at different times, which can introduce bias in the estimates due to time trends. In this article, we present methods to incorporate non-concurrent control data in treatment-control comparisons, allowing for time trends. We focus mainly on frequentist approaches that model the time trend and Bayesian strategies that limit the borrowing level depending on the heterogeneity between concurrent and non-concurrent controls. We examine the impact of time trends, overlap between experimental treatment arms and entry times of arms in the trial on the operating characteristics of treatment effect estimators for each method under different patterns for the time trends. We argue under which conditions the methods lead to type 1 error control and discuss the gain in power compared to trials only using concurrent controls by means of a simulation study in which methods are compared.

AB - Shared controls in platform trials comprise concurrent and non-concurrent controls. For a given experimental arm, non-concurrent controls refer to data from patients allocated to the control arm before the arm enters the trial. The use of non-concurrent controls in the analysis is attractive because it may increase the trial's power of testing treatment differences while decreasing the sample size. However, since arms are added sequentially in the trial, randomization occurs at different times, which can introduce bias in the estimates due to time trends. In this article, we present methods to incorporate non-concurrent control data in treatment-control comparisons, allowing for time trends. We focus mainly on frequentist approaches that model the time trend and Bayesian strategies that limit the borrowing level depending on the heterogeneity between concurrent and non-concurrent controls. We examine the impact of time trends, overlap between experimental treatment arms and entry times of arms in the trial on the operating characteristics of treatment effect estimators for each method under different patterns for the time trends. We argue under which conditions the methods lead to type 1 error control and discuss the gain in power compared to trials only using concurrent controls by means of a simulation study in which methods are compared.

KW - stat.ME

M3 - Preprint

BT - Treatment-control comparisons in platform trials including non-concurrent controls

ER -